DISCO Pharmaceuticals Welcomes New Leadership
Mark Manfredi brings over two decades of international biopharmaceutical industry leadership and cancer drug discovery success to DISCO Pharmaceuticals.
The recent financing will support the development of novel surfaceome-targeted therapies for hard-to-treat tumors.
Mark Manfredi's Appointment as CEO
DISCO Pharmaceuticals, a biopharmaceutical company focused on oncology, recently announced the appointment of Mark Manfredi, Ph.D., as its Chief Executive Officer (CEO). Mark takes over from Roman Thomas, M.D., the company’s founder and previous CEO, who will continue to provide strategic guidance. With this transition, DISCO aims to enhance its innovative approach to cancer treatment.
The Seed Financing Round
Alongside the CEO appointment, DISCO Pharmaceuticals has successfully closed a €36 million seed financing round. This round was co-led by two prominent investors, Ackermans & van Haaren and NRW.Bank, with additional support from investors like Sofinnova Partners, AbbVie Ventures, M Ventures, and Panakes Partners. This funding is crucial for advancing the company's exciting pipeline of surfaceome-targeted drug candidates, especially in the realm of small cell lung cancer and microsatellite-stable colorectal cancer.
Advancement in Cancer Treatments
Mark Manfredi emphasizes DISCO's mission to create differentiated therapies by leveraging its proprietary platform to identify novel cell-surface target pairs. This innovative approach positions DISCO to not only advance existing lead programs but also to expand its treatment pipeline. The focus remains on indication-specific and pan-tumor therapies that hold the potential to significantly impact patient care.
Expertise Behind the Leadership
With over 20 years of experience in the biopharmaceutical industry, Mark has previously held the CEO position at Ikena Oncology and served as an Entrepreneur in Residence at Atlas Venture. His extensive background includes leadership roles at Raze Therapeutics and Takeda Pharmaceuticals, where he played a significant part in developing global oncology R&D strategies.
Innovative Drug Development
DISCO Pharmaceuticals aims to transform cancer treatment through its innovative platform that uncovers previously unknown targets on cancer cell surfaces. As Mark Manfredi steps into the role of CEO, the company is set to harness his expertise in guiding its trajectory toward becoming a leader in surfaceome-guided drug development.
Mark expresses gratitude toward Roman Thomas for his foundational leadership that has brought DISCO to the current pivotal stage in its growth. The next phase under Mark's leadership promises further advancements in the fight against cancer.
About DISCO Pharmaceuticals
DISCO Pharmaceuticals is dedicated to advancing a pipeline of selective, surfaceome-targeted therapies aimed at hard-to-treat tumors. By mapping the entire surface of cells, the company is on the forefront of designing bispecific antibody-drug conjugates (ADCs) and T-cell engagers that offer unprecedented therapeutic specificity and broad efficacy against tumors. This innovative strategy is set to revolutionize the landscape of cancer treatment.
Frequently Asked Questions
Who is the new CEO of DISCO Pharmaceuticals?
Mark Manfredi, Ph.D., has been appointed as the new CEO of DISCO Pharmaceuticals.
How much funding did DISCO Pharmaceuticals recently secure?
DISCO Pharmaceuticals closed a €36 million seed financing round to advance its drug development programs.
What is the focus of DISCO Pharmaceuticals?
DISCO is focused on developing surfaceome-targeted therapies for difficult-to-treat tumors, including small cell lung cancer and colorectal cancer.
What experience does Mark Manfredi bring to DISCO?
Mark has over 20 years of experience in the biopharmaceutical sector, with previous leadership roles in companies like Ikena Oncology and Takeda Pharmaceuticals.
What is unique about DISCO's drug development approach?
DISCO employs a proprietary platform to identify novel cell-surface target pairs, paving the way for groundbreaking cancer therapies.